Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × HDAC-42 × Clear all
NCT02569320 2021-06-15

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
9 enrolled
Plasma cell

Multiple Myeloma

NCT02795819 2019-10-24

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Virginia Commonwealth University

Phase 1 Terminated
6 enrolled 12 charts
GenitourinarySarcoma

Carcinoma, Renal Cell, Neoplasm Metastasis, Sarcoma

NCT01798901 2018-03-14

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
13 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡